Want to see TSE:LOVE full AI Analyst Report?
Total Valuation
Cannara Biotech has a market cap or net worth of C$179.78M. The enterprise value is C$180.34M.
Market CapC$179.78M
Enterprise ValueC$180.34M
Share Statistics
Cannara Biotech has 98,782,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,782,150
Owned by Insiders75.59%
Owned by Institutions―
Financial Efficiency
Cannara Biotech’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.86%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)10.86%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee237.43K
Profits Per Employee28.93K
Employee Count452
Asset Turnover0.64
Inventory Turnover1.35
Valuation Ratios
The current PE Ratio of Cannara Biotech is 17.4. Cannara Biotech’s PEG ratio is 0.13.
PE Ratio17.4
PS Ratio1.57
PB Ratio1.64
Price to Fair Value1.64
Price to FCF12.31
Price to Operating Cash Flow6.46
PEG Ratio0.13
Income Statement
In the last 12 months, Cannara Biotech had revenue of 107.32M and earned 13.08M in profits. Earnings per share was 0.14.
Revenue107.32M
Gross Profit47.22M
Operating Income22.20M
Pretax Income18.10M
Net Income13.08M
EBITDA28.18M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was 27.15M and capital expenditures -11.53M, giving a free cash flow of 15.63M billion.
Operating Cash Flow27.15M
Free Cash Flow15.63M
Free Cash Flow per Share0.16
Dividends & Yields
Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.26
52-Week Price Change2.25%
50-Day Moving Average1.71
200-Day Moving Average1.76
Relative Strength Index (RSI)59.12
Average Volume (3m)45.69K
Important Dates
Cannara Biotech upcoming earnings date is Jul 15, 2026, Before Open (Confirmed).
Last Earnings DateApr 14, 2026
Next Earnings DateJul 15, 2026
Ex-Dividend Date―
Financial Position
Cannara Biotech as a current ratio of 2.40, with Debt / Equity ratio of 28.47%
Current Ratio2.40
Quick Ratio1.10
Debt to Market Cap0.24
Net Debt to EBITDA0.97
Interest Coverage Ratio5.10
Taxes
In the past 12 months, Cannara Biotech has paid 5.02M in taxes.
Income Tax5.02M
Effective Tax Rate0.28
Enterprise Valuation
Cannara Biotech EV to EBITDA ratio is 6.93, with an EV/FCF ratio of 14.31.
EV to Sales1.82
EV to EBITDA6.93
EV to Free Cash Flow14.31
EV to Operating Cash Flow9.76
Balance Sheet
Cannara Biotech has C$21.90M in cash and marketable securities with C$34.22M in debt, giving a net cash position of -C$12.32M billion.
Cash & Marketable SecuritiesC$21.90M
Total DebtC$34.22M
Net Cash-C$12.32M
Net Cash Per Share-C$0.12
Tangible Book Value Per ShareC$1.09
Margins
Gross margin is 32.66%, with operating margin of 20.68%, and net profit margin of 12.18%.
Gross Margin32.66%
Operating Margin20.68%
Pretax Margin16.86%
Net Profit Margin12.18%
EBITDA Margin26.26%
EBIT Margin20.29%
Analyst Forecast
The average price target for Cannara Biotech is C$3.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$3.13
Price Target Upside70.77% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast19.35%
EPS Growth Forecast-26.04%